Skip to main content

Advertisement

Table 5 Mean change in central pulse pressure (mmHg) after EMPA therapy separated according to median of different variables

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 4.66 ± 8.87 − 4.77 ± 9.04 − 5.54 ± 8.25 − 1.03 ± 9.37 − 1.95 ± 11.9 − 3.978 ± 9.39 − 2.65 ± 9.46 − 1.82 ± 8.11
< median − 0.83 ± 9.27 − 0.84 ± 9.08 − 0.47 ± 9.43 − 4.45 ± 8.86 − 3.48 ± 5.82 − 1.51 ± 8.99 − 2.81 ± 9.13 − 3.67 ± 10.2
p-value 0.114 0.105 0.033 0.160 0.533 0.311 0.949 0.449
  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure